cbdmd inc - YCBD

YCBD

Close Chg Chg %
0.58 0.01 2.52%

Closed Market

0.59

+0.01 (2.52%)

Volume: 463.69K

Last Updated:

Dec 4, 2025, 3:59 PM EDT

Company Overview: cbdmd inc - YCBD

YCBD Key Data

Open

$0.59

Day Range

0.57 - 0.64

52 Week Range

0.47 - 6.54

Market Cap

$5.26M

Shares Outstanding

8.92M

Public Float

8.30M

Beta

2.23

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$6.19

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

959.71K

 

YCBD Performance

1 Week
 
-1.07%
 
1 Month
 
-23.86%
 
3 Months
 
-16.30%
 
1 Year
 
-83.73%
 
5 Years
 
-99.94%
 

YCBD Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About cbdmd inc - YCBD

cbdMD, Inc. engages in the business of operating cannabidiol brands such as Paw cannabidiol and cbdMD botanicals. Its product categories include CBD tinctures, gummies, topical, and bath bombs. The company was founded on March 17, 2015 and is headquartered in Charlotte, NC.

YCBD At a Glance

cbdMD, Inc.
2101 Westinghouse Boulevard
Charlotte, North Carolina 28273
Phone 1-704-445-3060 Revenue 19.48M
Industry Pharmaceuticals: Other Net Income -3,700,126.00
Sector Health Technology Employees 42
Fiscal Year-end 09 / 2025
View SEC Filings

YCBD Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.104
Price to Book Ratio 0.945
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -0.62
Enterprise Value to Sales 0.044
Total Debt to Enterprise Value 1.495

YCBD Efficiency

Revenue/Employee 463,861.119
Income Per Employee -88,098.238
Receivables Turnover 19.801
Total Asset Turnover 1.455

YCBD Liquidity

Current Ratio 0.741
Quick Ratio 0.448
Cash Ratio 0.285

YCBD Profitability

Gross Margin 55.67
Operating Margin -16.372
Pretax Margin -18.992
Net Margin -18.992
Return on Assets -27.637
Return on Equity -67.307
Return on Total Capital -114.434
Return on Invested Capital -55.234

YCBD Capital Structure

Total Debt to Total Equity 64.683
Total Debt to Total Capital 39.277
Total Debt to Total Assets 12.002
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cbdmd Inc - YCBD

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
44.48M 35.40M 24.16M 19.48M
Sales Growth
+6.20% -20.41% -31.77% -19.35%
Cost of Goods Sold (COGS) incl D&A
15.51M 14.90M 11.12M 8.64M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.25M 2.97M 2.93M 1.82M
Depreciation
2.21M 2.09M 1.53M 1.12M
Amortization of Intangibles
48.48K 884.38K 1.40M 697.51K
COGS Growth
-0.01% -3.95% -25.38% -22.33%
Gross Income
28.97M 20.50M 13.04M 10.85M
Gross Income Growth
+9.86% -29.22% -36.42% -16.81%
Gross Profit Margin
+65.13% +57.91% +53.97% +55.67%
2021 2022 2023 2024 5-year trend
SG&A Expense
48.58M 37.81M 22.31M 14.04M
Research & Development
- - - -
-
Other SG&A
48.58M 37.81M 22.31M 14.04M
SGA Growth
+10.54% -22.17% -41.01% -37.08%
Other Operating Expense
- - - -
-
Unusual Expense
5.22M 53.08M 13.03M 481.05K
EBIT after Unusual Expense
(24.84M) (70.39M) (22.30M) (3.67M)
Non Operating Income/Expense
- 576.36K 310.92K (636.30K)
Non-Operating Interest Income
- - 16.25K 63.70K
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 28.93K 29.51K
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - 28.93K 29.51K
-
Interest Capitalized
- - - -
-
Pretax Income
(24.29M) (70.08M) (22.94M) (3.70M)
Pretax Income Growth
-314.84% -188.53% +67.27% +83.87%
Pretax Margin
-54.61% -197.96% -94.96% -18.99%
Income Tax
- - - (895.00K)
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - (895.00K)
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(23.39M) (70.08M) (22.94M) (3.70M)
Minority Interest Expense
- - - -
-
Net Income
(23.39M) (70.08M) (22.94M) (3.70M)
Net Income Growth
-284.92% -199.57% +67.27% +83.87%
Net Margin Growth
-52.60% -197.96% -94.96% -18.99%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(23.39M) (70.08M) (22.94M) (3.70M)
Preferred Dividends
2.55M 4.00M 4.00M 4.00M
Net Income Available to Common
(25.95M) (74.09M) (26.94M) (7.70M)
EPS (Basic)
-170.0424 -446.3712 -106.5715 -14.2916
EPS (Basic) Growth
-270.40% -162.51% +76.12% +86.59%
Basic Shares Outstanding
152.61K 165.97K 252.79K 539.07K
EPS (Diluted)
-170.0424 -446.3712 -106.5715 -14.2916
EPS (Diluted) Growth
-274.39% -162.51% +76.12% +86.59%
Diluted Shares Outstanding
152.61K 165.97K 252.79K 539.07K
EBITDA
(17.36M) (14.34M) (6.34M) (1.37M)
EBITDA Growth
-10.72% +17.41% +55.78% +78.41%
EBITDA Margin
-39.03% -40.51% -26.25% -7.03%

Snapshot

Average Recommendation BUY Average Target Price 2.00
Number of Ratings 1 Current Quarters Estimate -0.05
FY Report Date 12 / 2025 Current Year's Estimate -0.20
Last Quarter’s Earnings -0.07 Median PE on CY Estimate N/A
Year Ago Earnings -1.08 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 1 1 N/A
Mean Estimate -0.05 -0.05 -0.20 N/A
High Estimates -0.05 -0.05 -0.20 N/A
Low Estimate -0.05 -0.05 -0.20 N/A
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Cbdmd Inc - YCBD

Date Name Shares Transaction Value
May 21, 2025 Jeffrey Howard Porter Director 1,572 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Bakari Sellers Director 2,752 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Scott G. Stephen Director 2,840 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 William F. Raines Director 12,104 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Sibyl Swift Director 2,573 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Kevin Roe Director 25,135 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Cbdmd Inc in the News